Physician profile

John L Culleton

Endocrinology, Diabetes & Metabolism · Florence, SC

NPI 1619917309

$1,454.31

in general payments reported to CMS, 2019-2025

21 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbott Laboratories $421.31 2020
Insulet Corporation $181.61 2019-2022
Medtronic Minimed, INC. $119.69 2019-2020
Merck Sharp & Dohme LLC $104.86 2019-2021
Mannkind Corporation $100.79 2019-2020
Lilly USA, LLC $72.04 2019-2022
Amgen INC. $62.98 2019-2022
Novo Nordisk INC $55.73 2019-2020
Xeris Pharmaceuticals, INC. $53.60 2021-2022
Sanofi-Aventis U.S. LLC $42.49 2019
Astrazeneca Pharmaceuticals Lp $36.68 2019-2020
Corcept Therapeutics $31.86 2021-2022
Shire North American Group INC $28.91 2019
Amarin Pharma, INC. $26.47 2019-2020
Becton, Dickinson and Company $21.17 2019
Show all 21 companies
CompanyGeneral paymentsYearsTop products
Horizon Therapeutics Plc $19.41 2022
Companion Medical, INC. $17.41 2020
Valeritas, INC. $15.89 2019
Abbvie INC. $14.87 2019
Ibsa Pharma INC. $14.61 2019
Boehringer Ingelheim Pharmaceuticals, INC. $11.93 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

John L Culleton

$1,454.31

in general payments reported 2019-2025

Years
2019-2022
Top company
Abbott Laboratories

https://glasscript.com/doctor/345267/john-l-culleton

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.